Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis
- 1 May 2006
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 6 (5) , 360-368
- https://doi.org/10.1038/nrc1879
Abstract
Endometrial cancer is the most common gynaecological malignancy. Although no specific gene or genes have been linked to the majority of cases of endometrial cancer, several well-characterized oncogenes and tumour-suppressor genes have been implicated in endometrial carcinogenesis. Approximately 80% of endometrial cancer cases are type I tumours, which are usually well differentiated and endometrioid in histology, and are associated with a history of unopposed oestrogen exposure or other hyperoestrogenic risk factors such as obesity. Oestrogen and selective oestrogen-receptor modulators (SERMs) are implicated in endometrial carcinogenesis through regulation of gene transcription. Oestrogen and SERMs exert their carcinogenic roles in the endometrium through their downstream molecular effectors such as PAX2 (paired box gene 2).Keywords
This publication has 123 references indexed in Scilit:
- Ligand-dependent switching of ubiquitin–proteasome pathways for estrogen receptorThe EMBO Journal, 2004
- Tamoxifen: a most unlikely pioneering medicineNature Reviews Drug Discovery, 2003
- Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cellsOncogene, 2002
- Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expressionOncogene, 2001
- EXPRESSION OF THE DEVELOPMENTAL AND ONCOGENIC PAX2 GENE IN HUMAN PROSTATE CANCERJournal of Urology, 2001
- Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated TranscriptionCell, 2000
- Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 SitesScience, 1997
- Agonistic Effect of Tamoxifen Is Dependent on Cell Type, ERE-Promoter Context, and Estrogen Receptor Subtype: Functional Difference between Estrogen Receptors α and βBiochemical and Biophysical Research Communications, 1997
- Recent and Past Use of Conjugated Estrogens in Relation to Adenocarcinoma of the EndometriumNew England Journal of Medicine, 1980
- A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474British Journal of Cancer, 1971